Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. A
A logo

A Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
115.200
Open
112.550
VWAP
113.69
Vol
2.47M
Mkt Cap
32.21B
Low
111.895
Amount
280.76M
EV/EBITDA(TTM)
18.07
Total Shares
282.60M
EV
33.25B
EV/OCF(TTM)
23.82
P/S(TTM)
4.51
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Show More

Events Timeline

(ET)
2026-03-26
08:10:00
Agilent Receives FDA Approval for PD-L1 IHC 22C3 as KEYTRUDA Companion Diagnostic
select
2026-03-23 (ET)
2026-03-23
08:20:00
MaxCyte Appoints Parmeet Ahuja as CFO
select
2026-03-09 (ET)
2026-03-09
05:20:00
Agilent Acquires Biocare Medical for $950M
select

News

Marketbeat
8.5
03-29Marketbeat
The Overlooked Sector of Healthcare That Has Captivated Wall Street
  • Health Care Industry Volatility: The health care sector is characterized by significant volatility, with companies experiencing drastic changes in stock prices based on the success of individual products or clinical trials.

  • Investment Trends: Investors are increasingly focusing on companies that provide essential equipment and services rather than high-risk pharmaceutical names, despite some major players in the lab equipment sector being overlooked.

  • Thermo Fisher's Performance: Thermo Fisher Scientific has faced challenges in 2026, with shares dropping over 15% year-to-date, but recent revenue growth and strong earnings suggest potential for recovery.

  • Agilent's Growth Potential: Agilent Technologies is expected to see significant growth in earnings and share price, driven by its recent acquisition of BioCare Medical, which enhances its capabilities in cancer diagnostics.

NASDAQ.COM
9.0
03-26NASDAQ.COM
Agilent Receives FDA Approval for New Diagnostic Tool
  • FDA Approval for New Indication: Agilent Technologies announced that its PD-L1 IHC 22C3 pharmDx (Code SK006) has received FDA approval as a companion diagnostic to help identify patients with esophageal or gastroesophageal junction carcinoma eligible for Merck's KEYTRUDA treatment, further solidifying its position in precision medicine.
  • Eighth Indication: This approval marks the eighth FDA-approved indication for PD-L1 IHC 22C3 pharmDx, showcasing the product's broad application potential in cancer treatment, which may drive Agilent's growth in the clinical diagnostics market.
  • Positive Market Reaction: In pre-market trading on the NYSE, Agilent shares rose by 0.46% to $113.48, reflecting investor confidence in the company's newly approved product and optimistic expectations for its future market performance.
  • Supporting Clinical Decisions: Nina Green, Vice President and General Manager of Agilent's Clinical Diagnostics Division, stated that the expanded FDA approval of PD-L1 IHC 22C3 pharmDx will assist clinicians in better identifying patients suitable for KEYTRUDA treatment, thereby enhancing treatment efficacy and patient survival rates.
Newsfilter
8.5
03-26Newsfilter
Agilent Receives FDA Approval for New Diagnostic Tool
  • FDA Approval: Agilent Technologies has received FDA approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic tool aimed at identifying patients with esophageal or gastroesophageal junction carcinoma eligible for KEYTRUDA treatment, marking a significant advancement in the field of precision medicine.
  • Market Demand Response: This diagnostic tool is specifically designed to identify patients with PD-L1 expression ≥ 1, which is expected to significantly enhance treatment options for esophageal cancer patients, addressing the urgent market demand for precision therapies and reinforcing Agilent's leadership in the cancer diagnostics market.
  • Multiple Indications: In addition to esophageal cancer, PD-L1 IHC 22C3 pharmDx is also indicated for identifying patients with non-small cell lung cancer, cervical cancer, and other cancers, thereby broadening its market application and enhancing Agilent's product competitiveness.
  • Strong Financial Performance: Agilent reported revenues of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people; with the launch of this new diagnostic tool, future revenue growth is anticipated, solidifying its position in the global clinical diagnostics market.
seekingalpha
5.0
03-23seekingalpha
Crawford & Company Appoints New CEO
  • New CEO Appointment: Crawford & Company has appointed W. Bruce Swain Jr. as President and CEO effective immediately, having served in an interim capacity since January 1, which reflects the company's confidence in his leadership capabilities.
  • Board Changes: Board member Jesse C. Crawford Sr. announced he will not seek re-election at the 2026 annual shareholder meeting, marking the end of over four decades with the firm, indicating a significant shift in the company's governance structure.
  • Honorary Title Bestowal: Following the shareholder meeting, Crawford Sr. will be named an honorary board member and emeritus officer, recognizing his long-term contributions while facilitating a smooth transition to the new board.
  • Future Outlook: The company anticipates a subdued claims environment in Q1 2026, reflecting current market challenges and uncertainties that may impact overall performance, highlighting the need for strategic adjustments moving forward.
Newsfilter
7.5
03-11Newsfilter
Agilent Launches Advanced Therapeutics CDMO Solution
  • Integrated Manufacturing Capabilities: Agilent's launch of the Advanced Therapeutics solution combines the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado, offering a comprehensive suite of customizable manufacturing services that enhance the company's competitiveness in the biopharmaceutical sector.
  • Diverse Product Portfolio: The CDMO portfolio includes oligonucleotides, microbial fermentation, complex synthetic chemistry, highly potent APIs, and cell line development, catering to diverse client needs in clinical and commercial-scale production, thereby driving business growth.
  • Enhanced Customer Experience: By providing a streamlined, end-to-end service from discovery to clinical and commercial-scale manufacturing, Agilent creates a more integrated experience for clients, deepening technical partnerships and building customer trust.
  • Long-Term Commitment: Agilent's CEO Padraig McDonnell emphasizes that this launch reflects the company's long-term commitment to growth, investment, and leadership in the industry, aimed at supporting clients in developing life-changing therapies.
Benzinga
8.5
03-09Benzinga
Agilent Acquires Biocare Medical for $950 Million
  • Acquisition Overview: Agilent Technologies announced the acquisition of Biocare Medical for approximately $950 million, with the deal expected to close in the fourth fiscal quarter of 2026, enhancing its market position in pathology.
  • Growth Potential: Biocare Medical boasts over 300 specialized antibodies and strong R&D capabilities, achieving double-digit revenue and profit growth since 2021, which is anticipated to significantly boost Agilent's revenue growth and margins.
  • Market Integration Impact: The acquisition will integrate Biocare's product portfolio into Agilent's Life Sciences and Diagnostics Markets Group, expected to enhance its ability to develop and commercialize new IVD antibodies, thereby expanding its reach across clinical and research pathology labs.
  • Stock Performance Analysis: Despite a 5.60% decline in Agilent's stock over the past 12 months, currently trading at $116.41, below its 20-day and 50-day SMAs, the strategic acquisition of Biocare may improve its market performance in the future.
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
Wall Street analysts forecast A stock price to rise
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
160.00
Averages
171.67
High
180.00
Current: 0.000
sliders
Low
160.00
Averages
171.67
High
180.00
Nephron Research
Jack Meehan
Hold
to
Buy
upgrade
$145
AI Analysis
2026-03-26
Reason
Nephron Research
Jack Meehan
Price Target
$145
AI Analysis
2026-03-26
upgrade
Hold
to
Buy
Reason
Nephron Research analyst Jack Meehan upgraded Agilent to Buy from Hold with a $145 price target.
Citi
Buy
maintain
$185
2026-03-11
Reason
Citi
Price Target
$185
2026-03-11
maintain
Buy
Reason
Citi opened an "upside 90-day catalyst watch" on shares of Agilent while keeping a Buy rating on the name with a $185 price target. The share overhang of a potential transformational acquisition should be removed with Agilent's deal for Biocare Medical, the analyst tells investors in a research note. Citi sees the stock's multiple rebounding.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for A
Unlock Now

Valuation Metrics

The current forward P/E ratio for Agilent Technologies Inc (A.N) is 18.71, compared to its 5-year average forward P/E of 25.17. For a more detailed relative valuation and DCF analysis to assess Agilent Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.17
Current PE
18.71
Overvalued PE
29.41
Undervalued PE
20.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.58
Current EV/EBITDA
16.67
Overvalued EV/EBITDA
23.69
Undervalued EV/EBITDA
17.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.76
Current PS
4.03
Overvalued PS
6.56
Undervalued PS
4.95

Financials

AI Analysis
Annual
Quarterly

Whales Holding A

X
XTX Markets Limited
Holding
A
+11.12%
3M Return
R
RobecoSAM AG
Holding
A
+10.03%
3M Return
S
Schonfeld Strategic Advisors LLC
Holding
A
+9.54%
3M Return
P
Pacific Heights Asset Management, LLC
Holding
A
+6.04%
3M Return
A
AlphaQuest LLC
Holding
A
+5.88%
3M Return
S
Scout Investments, Inc.
Holding
A
+5.63%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Agilent Technologies Inc (A) stock price today?

The current price of A is 113.98 USD — it has increased 1.76

What is Agilent Technologies Inc (A)'s business?

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

What is the price predicton of A Stock?

Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is171.67 USD with a low forecast of 160.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Agilent Technologies Inc (A)'s revenue for the last quarter?

Agilent Technologies Inc revenue for the last quarter amounts to 1.80B USD, increased 6.96

What is Agilent Technologies Inc (A)'s earnings per share (EPS) for the last quarter?

Agilent Technologies Inc. EPS for the last quarter amounts to 1.07 USD, decreased -3.60

How many employees does Agilent Technologies Inc (A). have?

Agilent Technologies Inc (A) has 18100 emplpoyees as of April 01 2026.

What is Agilent Technologies Inc (A) market cap?

Today A has the market capitalization of 32.21B USD.